MiNK Therapeutics Files 8-K on Operations and Financials
Ticker: INKT · Form: 8-K · Filed: Aug 14, 2025 · CIK: 1840229
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
MiNK Therapeutics filed an 8-K on Aug 14, 2025, detailing its financials and operations.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as AgenTus Therapeutics, Inc., with a name change effective January 12, 2021.
Why It Matters
This 8-K filing provides an update on MiNK Therapeutics' financial health and operational status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant adverse events.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- AgenTus Therapeutics, Inc. (company) — Former company name
- January 12, 2021 (date) — Date of name change
- 149 Fifth Avenue, Suite 500 (address) — Principal Executive Offices
- New York, New York 10010 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on MiNK Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 14, 2025.
What was MiNK Therapeutics, Inc. formerly known as?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc.
When did the company change its name from AgenTus Therapeutics, Inc.?
The company's name change from AgenTus Therapeutics, Inc. was effective on January 12, 2021.
Where are MiNK Therapeutics, Inc.'s principal executive offices located?
MiNK Therapeutics, Inc.'s principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-08-14 07:35:28
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share INKT The NASDAQ Cap
Filing Documents
- f8k_081425.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 26KB
- 0001171843-25-005405.txt ( ) — 240KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_081425_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 14, 2025, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated August 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: August 14, 2025 By: /s/ Christine M. Klaskin Christine M. Klaskin Principal Financial Officer